CANbridge Pharmaceuticals Inc. (HKG:1228)
Hong Kong · Delayed Price · Currency is HKD | Market Cap | 1.16B +1,924.5% |
| Revenue (ttm) | 55.62M -41.3% |
| Net Income | 16.49M |
| EPS | 0.03 |
| Shares Out | 595.44M |
| PE Ratio | 58.41 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 20,000 |
| Open | 1.950 |
| Previous Close | 1.950 |
| Day's Range | 1.950 - 1.950 |
| 52-Week Range | 0.249 - 3.500 |
| Beta | -0.07 |
| Analysts | Strong Buy |
| Price Target | 12.30 (+530.77%) |
| Earnings Date | Aug 28, 2026 |
About CANbridge Pharmaceuticals
CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy (ERT) for the treatment of Hunter syndrome; and Livmarli, an oral, minimally-absorbed, reversible ileal bile acid transporter inhibitor for the treatment of alagille syndrome and progressive familial intrahepatic cholestasis. It also develops CAN106, an anti-C5 mAb for paroxysmal nocturnal hemoglobinu... [Read more]
News
CANbridge Pharmaceuticals Earnings release: H2 2025
CANbridge Pharmaceuticals released its H2 2025 earnings on March 30, 2026, summarizing the period's financial results.
CANbridge Pharmaceuticals Annual report: H2 2025
CANbridge Pharmaceuticals has published its H2 2025 annual report on March 30, 2026.
CANbridge Pharmaceuticals Quarterly report: H1 2025
CANbridge Pharmaceuticals has published its H1 2025 quarterly earnings report on August 31, 2025.
CANbridge Pharmaceuticals Earnings release: H1 2025
CANbridge Pharmaceuticals released its H1 2025 earnings on August 31, 2025, summarizing the period's financial results.
China's Push To Expand Access To Costly Therapies And A Partnership Deal Boost Rare Drugs Maker - But Is It Enough?
The maker of drugs for rare diseases has enjoyed an explosive rise in its share price, helped by a partnership deal and Chinese moves to widen access to costly therapies Key Takeaways： A drug distribu...